VIV — Avivagen Income Statement
0.000.00%
Last trade - 00:00
- CA$0.39m
- CA$7.61m
- CA$0.94m
- 17
- 51
- 16
- 18
2018 October 31st | 2019 October 31st | 2020 October 31st | 2021 October 31st | 2022 October 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.07 | 0.977 | 1.18 | 1.3 | 0.939 |
Cost of Revenue | |||||
Gross Profit | 0.654 | 0.526 | 0.471 | 0.534 | 0.4 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Operating Interest Expense / Income | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 5.91 | 5.81 | 5.93 | 7.69 | 7.01 |
Operating Profit | -4.83 | -4.84 | -4.75 | -6.39 | -6.07 |
Net Income Before Taxes | -4.83 | -4.84 | -4.75 | -6.39 | -6.07 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.83 | -4.84 | -4.75 | -6.39 | -6.07 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.83 | -4.84 | -4.75 | -6.39 | -6.07 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.83 | -4.84 | -4.75 | -6.39 | -6.07 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.139 | -0.139 | -0.133 | -0.125 | -0.093 |